United States v. Mark Lou Meyer

483 F.3d 865, 2007 U.S. App. LEXIS 9370, 2007 WL 1201880
CourtCourt of Appeals for the Eighth Circuit
DecidedApril 25, 2007
Docket06-2961
StatusPublished
Cited by29 cases

This text of 483 F.3d 865 (United States v. Mark Lou Meyer) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Mark Lou Meyer, 483 F.3d 865, 2007 U.S. App. LEXIS 9370, 2007 WL 1201880 (8th Cir. 2007).

Opinion

O’CONNOR, Associate Justice (Ret).

Mark Lou Meyer appeals the district court’s revocation of his probation. Because the district court’s factual findings on the two grounds on which it justified revoking Meyer’s probation were not clearly erroneous, we affirm the judgment below.

I.

On January 22, 2004, Mark Lou Meyer was indicted for being an unlawful drug user in possession of a firearm, in violation of 18 U.S.C. § 922(g)(3). After Meyer pleaded guilty to this charge, the district court sentenced him to a term of three years’ probation on September 2, 2004. As relevant to this appeal, Meyer’s probation came with two conditions. First, Meyer was prohibited from possessing or using unlawful drugs. Second, Meyer was prohibited from leaving Iowa’s Northern District without first obtaining permission from a probation officer or the court.

While he was on probation, Meyer participated in two distinct methods of drug testing. Under the first method, a probation officer affixed sweat patches to Meyer’s skin to monitor whether he was using illegal drugs. The sweat patch technology at issue here is a relatively novel drug testing device. The sweat patch, which is “marketed by PharmChem, Inc., is composed of an absorbent pad and an outer membrane. After the skin is cleaned with alcohol, the patch is applied to the wearer[], and the absorbent pad collects the wearer’s sweat, over a period of a week or more.” United States v. Bentham, 414 F.Supp.2d 472, 473 (S.D.N.Y.2006). “The [wearerj’s sweat wets the pad, the water in the sweat eventually evaporates through the non-occlusive membrane, and any drugs remain in the absorbent pad. Once the sweat patch is removed from the [wearer], it is returned to PharmChem for analysis.” United States v. Snyder, 187 F.Supp.2d 52, 58 (N.D.N.Y.2002). “If the absorbent patch is removed from the skin, it cannot be reattached.” Id. “The patch has been ‘cleared’ by the Food and Drug Administration for use as a drug testing device and is used widely in the criminal justice system because of its perceived advantages over other forms of drug testing, e.g., its non-invasiveness, resistance to intentional adulteration, and ability to detect drug-use over relatively long periods.” Bentham, 414 F.Supp.2d at 473.

Beginning in November 2005 and ending in June 2006, Meyer submitted some sixteen sweat patches for drug testing. The first seven patches that Meyer submitted revealed no illegal substances. Because the eighth patch that Meyer submitted somehow managed to come dislodged from his skin, the district court declined to treat it as a drug test (even though this patch did, in fact, test positive for cocaine). Each of the remaining eight patches that Meyer submitted tested positive for cocaine and benzoylecgonine, a cocaine metabolite. The presence of benzoylecgonine indicates that Meyer’s body had processed the cocaine.

In addition to submitting sweat patches, Meyer simultaneously participated in a urinalysis program while he was on probation. From March 2006 until June 2006, Meyer submitted numerous urine samples, which were tested for controlled sub *867 stances. In contrast to the sweat patches that Meyer submitted during this same period, none of the urine samples that Meyer submitted indicated that he had been using unlawful drugs.

In light of the positive sweat patch results, the United States filed a motion to revoke Meyer’s probation on May 31, 2006. Meyer denied violating his probation by taking illegal drugs. Accordingly, the district court held three evidentiary hearings in June and July of 2006. Dr. Leo Kadeh-jian, a biochemist who holds an undergraduate degree from the Massachusetts Institute of Technology and a doctorate from Stanford University, testified on behalf of the government. A consultant to the Administrative Office of the United States on drug testing, Dr. Kadehjian testified that the sweat patch was a scientifically reliable device. While he acknowledged that some academic papers concluded that sweat patches could become contaminated without the wearer having used drugs, Dr. Kadehjian thought that these papers did not correspond to real-world conditions. Furthermore, Dr. Kadehjian noted that laboratories will not report a sweat patch as testing positive for cocaine unless a metabolite of cocaine is found, which indicates that the wearer’s body has broken down cocaine.

Dr. Kadehjian further explained how Meyer’s negative urine results and positive sweat patch results could be reconciled. Because urinalysis tests will not reveal a drug if there is less than 300 nanograms of the drug per milliliter of urine, Dr. Kadeh-jian noted, it does not mean that the drug is altogether absent from a subject’s system. Rather, a negative drug test simply means that there is an insufficient amount of the drug in the subject’s system to trigger a positive result. In addition, whereas sweat patches monitor the individual’s drug usage twenty-four hours per day, Dr. Kadehjian explained that urine tests detect drugs for only about two days following cocaine usage. Dr. Kadehjian testified that Meyer’s sweat patch results revealed a relatively modest amount of cocaine usage, which could explain why Meyer’s urine tests came back negative.

Meyer declined to present expert testimony about the efficacy of sweat patches. In an effort to explain why his sweat patch results started indicating that he had used cocaine, Meyer offered the following:

I’ve stayed awake at nights trying to figure out what went wrong so it would return a positive without having any drugs in my system, without having done any drugs. I can come up with one possibility, that up until that point I was employed by a company who hauled high-end cars, Corvettes, Mercedeses, Jaguars, Cadillacs, all high end stuff, stuff that was going to clients who were rich people. I changed [to] hauling cars that were repossessed, bought from auctions, they weren’t cleaned, they weren’t detailed. There would have been any chance and every chance for me to come in contact with contamination from somebody that had done drugs in their cars, touched a steering wheel, touched the gearshift, touched the door handle. Somebody could have been smoking in there. It could have been in the headliner. I came in contact with things like that.

Revocation Hearing Tr. at 109-10.

The district court also heard testimony from Lisa Feuerbach, Meyer’s probation officer. Officer Feuerbach testified that she contacted Meyer on May 1, 2006 to request that he provide a urine sample. Meyer informed Officer Feuerbach that he would be unable to do so because he had taken it upon himself to travel to Illinois to submit a hair sample for drug testing. (That hair sample, Meyer noted, ultimately tested negative for drug usage.) Officer *868 Feuerbach testified that Meyer had not submitted a travel request form and further indicated that she had not given Meyer permission to travel outside of Iowa. Although Meyer claimed that he needed to drive to Aurora, Illinois so that a laboratory technician from Omega Laboratories could collect a hair sample, the government introduced evidence from Omega’s website indicating otherwise.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In the Interest of A.B., Minor Child
Court of Appeals of Iowa, 2023
In the Interest of A.C., Minor Child
Court of Appeals of Iowa, 2020
United States v. Chad Hall
Eighth Circuit, 2019
United States v. Tavares Montgomery
896 F.3d 875 (Eighth Circuit, 2018)
United States v. Craig Thomas
Eighth Circuit, 2018
United States v. Jones
861 F.3d 687 (Seventh Circuit, 2017)
United States v. Keefer Jones
Seventh Circuit, 2017
United States v. Brandon Devos
692 F. App'x 310 (Eighth Circuit, 2017)
United States v. Cheyenne Gonzales
681 F. App'x 568 (Eighth Circuit, 2017)
United States v. Darrell Andersen
679 F. App'x 515 (Eighth Circuit, 2017)
United States v. Terrell Simpson
643 F. App'x 613 (Eighth Circuit, 2016)
United States v. Karina Carrasco
633 F. App'x 355 (Eighth Circuit, 2016)
United States v. James Haney
637 F. App'x 262 (Eighth Circuit, 2016)
United States v. Heather Tolliver
637 F. App'x 245 (Eighth Circuit, 2016)
United States v. Roy Carrion
457 F. App'x 405 (Fifth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
483 F.3d 865, 2007 U.S. App. LEXIS 9370, 2007 WL 1201880, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-mark-lou-meyer-ca8-2007.